SLC5A2 and prostate carcinoma: In the analyses validating the influence of glucose, we found little genetic and observational evidence to support an association of HbA1c with prostate cancer, which implies a possible non-glucose mechanism of SGLT2 inhibition on prostate cancer prevention.